Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05225298 · ClinicalTrials.gov registry record · NA
SARS-COV-2 Screening in Dialysis Facilities
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 2,389
- Enrollment target
NCT05225298: Completed NA study, sponsored by Stanford University.
NCT05225298 is a NA study that has completed, run by Stanford University. The registered enrollment target is 2,389 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05225298, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,389 participants
- Enrollment target
Study Summary
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Interventions
- BEHAVIORAL Offering SARS-CoV-2 test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,389 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2023-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05225298
The ClinicalTrials.gov registry entry for NCT05225298 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Offering SARS-CoV-2 test is the first listed.
NCT05225298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05225298 about?
NCT05225298 is a clinical study titled "SARS-COV-2 Screening in Dialysis Facilities". Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and ...
What is the current status of trial NCT05225298?
This trial is currently completed. It is a NA study. The enrollment target is 2,389 participants. The study started on 2023-02-06. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT05225298?
The interventions under investigation include: Offering SARS-CoV-2 test (BEHAVIORAL).
Who is sponsoring clinical trial NCT05225298?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.